Category: Science

  • Call for paper abstracts

    Call for paper abstracts

    CORESTA is calling for the submission of abstracts of papers intended for presentation at this year’s Joint Study Group meetings.

    The Smoke Science and Product Technology (SSPT) meeting is due to be held at Kitzbühel, Austria, on October 8-12.

    And the Agronomy & Leaf Integrity and Phytopathology & Genetics (AP) meeting is scheduled to be held at Santa Cruz do Sul, Brazil, on October 22-26.

    The invitation for abstract submissions is being made through the CORESTA website at www.coresta.org, and will be made also through the official meeting websites in the near future.

    SSPT abstracts can be submitted directly at: https://www.coresta.org/events/smoke-techno-joint-study-groups-meeting-sspt2017-30439.html.

    And AP abstracts can be submitted directly at: https://www.coresta.org/events/agro-phyto-joint-study-groups-meeting-ap2017-30440.html.

    The deadline for the submission of abstracts is May 19.

    Authors will receive an immediate receipt message by e-mail to confirm successful submission of their abstract.

    They will be informed of the CORESTA Reading Committee’s selection towards the end of June.

  • Snus provides protection

    Snus provides protection

    Investigators in Sweden, Italy and the US have reported that ‘non-smoking men who used snus had a substantially reduced risk of Parkinson’s disease…’, according to a US public health expert.

    Writing on his blog on Wednesday, University of Louisville professor Brad Rodu said the research, published in the International Journal of Epidemiology, had combined data from seven Swedish cohort studies involving nearly 350,000 men.  The subjects were classified according to tobacco use and diagnosis of Parkinson’s disease over an average 16 years of follow-up.

    Rodu said the principal results were impressive. Among never-tobacco smokers, Parkinson’s disease risk in ever-snus users was lower than in never-users.

    Current-snus use was associated with a lower Parkinson’s disease risk than was former use.

    And there was evidence of dose-response relationships.

    The bottom line, Rodu said, was that current snus use, not former use, was strongly protective against Parkinson’s disease, with more protection from heavier and long-term use.

    This is not the first such finding. In 2009, Rodu discussed research from the American Cancer Society showing a similar strong protective effect.

    ‘Further, Parkinson’s may not be the only nerve illness for which smokeless tobacco and/or nicotine use is protective,’ Rodu said.

    Snus users had a significantly lower risk for multiple sclerosis than did non-users of tobacco.

    Nicotine had been found to improve performance in people with mild cognitive impairment, and it might also benefit those with Alzheimer’s disease.

    Rodu said that the current study represented a new era in Swedish snus research conducted by the Swedish Collaboration on Health Effects of Snus Use.

    He said he hoped that the Swedish Collaboration, with investigators from multiple universities in Sweden and beyond, would produce valuable, unbiased research on the health impact of snus use.

    Rodu’s annotated blog is at: http://rodutobaccotruth.blogspot.co.uk/

  • Abstract submission deadline nears

    Abstract submission deadline nears

    The deadline for the submission of abstracts for oral presentations at next year’s Global Forum on Nicotine (GFN) is January 31, while the deadline for the submission of poster presentations is March 31.

    The GFN is due to be held at the Marriott Centrum Hotel, Warsaw, Poland on June 15-17.

    The organizers say that the main program, which is scheduled for June 16 and 17, ‘will examine the rapidly developing science in relation to nicotine use and the changing landscape, including policy responses and the influence of different stakeholders in this’.

    The program will comprise plenary sessions, symposia, panel discussions and poster presentations – including video posters.

    The event will include, on June 15, satellite and side meetings, including one for consumers, organised by the International Network of Nicotine Consumer Organisations. It will include, too, the fourth Michael Russell Memorial Oration.

    Meanwhile, the first International Symposium on Nicotine Technology will be held alongside the GFN.

    Details of the GFN 2017 are at: https://gfn.net.co/

    Information about previous GFNs, including videos, presentations, photographs and reports, are available at https://gfn.net.co/conference-archives.

  • Ibuprofen cuts lung cancer risk

    Ibuprofen cuts lung cancer risk

    Regular use of ibuprofen might reduce the risk of dying from lung cancer, according to study findings presented at the IASLC (International Association for the Study of Lung Cancer) 17th World Conference on Lung Cancer (WCLC) in Vienna, Austria.

    A report in the Inquisitr yesterday said this possible benefit seemed to apply to both former smokers and current smokers.

    It quoted researchers involved in the study as suggesting that regular ibuprofen use might lower the risk of lung cancer death.

    The idea that ibuprofen use might reduce risks associated with smoking didn’t appear out of the blue. Earlier studies had associated inflammation with an increased risk of lung cancer; so the question arose as to whether the regular use of an anti-inflammatory medication would have a positive effect.

    Dr. Marisa Bittoni, of Ohio State University, US, and fellow researchers set out to examine this question, analyzing data from 10,735 adults who participated in the US’ Third National Health and Nutrition Examination Survey (NHANES III).

    The team looked at the subject’s use of ibuprofen and other nonsteroidal anti-inflammatory drugs, their smoking status, and other lifestyle factors. The participants followed up for an average of almost two decades while participating in the NHANES III.

    The team discovered that former and current smokers who used ibuprofen regularly were 48 percent less likely to die from lung cancer than those who did not use ibuprofen regularly.

    The full story is at: http://www.inquisitr.com/3808068/ibuprofen-reduces-risk-of-death-from-lung-cancer-among-former-and-current-smokers-researchers-say/

  • CORESTA documents available

    CORESTA documents available

    The CORESTA secretariat says that a number of documents, reports and news pieces have been published, and can be accessed on its website. The following documents have been published and can be downloaded from the CORESTA website at www.coresta.org under the Documents section.

    • Method No. 6 “Determination of Ventilation – Definitions and Measurement Principles” (2016-09-26)
    • Report “Recommendation of Measurement Area for Air Permeability Determination of Super-Slim Cigarette Papers” (2016-09-26)
    • Report “3rd Round Robin Test for Multi-Capillary Ventilation Calibration Standards 2014/2015” (2016-11-17)
    • Guide No. 18 “Technical Guide for Sample Handling and Sample Collection of E-Cigarettes and E-Vapour Generating Products” (2016-11-29)

    The following new projects were launched and a CORESTA Recommended Method (CRM) was entered into the ISO Standards process.  A full list of active projects is available on the CORESTA website at www.coresta.org under the Study Groups/Active Projects section:

    • Project 122:  PTM SG – 10th Proficiency Test on Physical Parameters
    • Project 123:  PTM SG – 3rd Proficiency Test on Diffusion Capacity
    • Project 124:  PTM SG – 5th Round Robin Test on Filter Ventilation Calibration Standards
    • Project 125:  STS SG – Metals Proficiency Study 2017
    • Project 126:  STS SG – TSNA, Moisture and pH Collaborative Study for CRM revision
    • Project 127:  EVAP SG – Carbonyl Method for Liquids and E-Vapour Product Aerosol
    • Project 128:  EVAP SG – Guide on Alternate Vaping Regimen(s) for E-Vapour Products
    • New ISO Project 21766CRM 72 – Determination of Tobacco Specific Nitrosamines in Smokeless Tobacco Products by LC-MS/MS

    Abstracts of presentations made at the 2016 CORESTA Congress in Berlin, Germany, are available from the CORESTA website at www.coresta.org under the Abstracts section. The CORESTA Sub-Group and Task Force reports presented at the 2016 CORESTA Congress have also been published and can be accessed on the individual group webpages on the CORESTA website. In addition, the abstracts of presentations made at the 70th Tobacco Science and Research Conference (TSRC) have been published under the CORESTA website Abstracts section. And the CORESTA Newsletter (Issue 46 – December 2016) is available for download in PDF format from the CORESTA website Home Page or the Information/Newsletters section.

  • No e-cigarette DNA damage

    No e-cigarette DNA damage

    Electronic cigarette vapor does not damage DNA, ‘even at doses 28 times that of equivalent smoke exposure’, British American Tobacco reports.

    Scientists at BAT used laboratory-based cellular tests to examine the impact of cigarette smoke and Vype e-cigarette vapor on human lung cells.

    The most serious kind of DNA damage occurs when there is a double-strand break, which effectively means that both strands of the DNA molecule have been broken. This is a possible precursor to cancer and is potentially lethal to the cell.

    “We have been able to show that there is significant DNA damage in human lung cells exposed to smoke, but that this is not [the] case with e-cigarette vapour,” said Dr. James Murphy, head of risk substantiation at BAT. “These findings add to evidence on the likely reduced risks of vaping, compared to smoking,” he said.

    The research is published in Toxicology Letters.

    ‘Cellular DNA can become damaged when exposed to toxicants, such as those in cigarette smoke,’ BAT said. ‘DNA double-strand break (DSB) in which both strands of the DNA molecule are broken, is the most serious type of DNA damage. The cell attempts to repair the DNA damage by modifying the protein or histone around which the DNA is wrapped. The changes observed in this histone can be used as an indicator of the level of DSB. These changes can be detected using a well-established test called a γH2AX assay.

    ‘This test was used to compare the impact of the 3R4F reference cigarette [a routinely used reference cigarette developed by the University of Kentucky, US, to ensure consistency in laboratory testing of cigarettes] and Vype ePen and Vype eStick (commercially available e-cigarettes) on human lung cells. This test was used in combination with an exposure system (Vitrocell VC) that allows lung cells to be exposed to aerosol in the lab in a way that mimics exposure in the body when consumers inhale.

    ‘This combination of tests allowed for the assessment of the whole aerosol, be it smoke or vapor. Previous studies focused on only the particulate fraction of smoke.

    ‘The results show that cigarette smoke induced significant DNA damage in human lung cells, in a dose dependent manner – that is, the higher the dose, the more DNA damage was induced. E-cigarette vapor produced no affect, even when the dose used was 28 times higher than the equivalent smoke exposure.

    ‘The results confirm that cigarette smoke is genotoxic (causes genetic damage) and, at higher doses, cytotoxic (can cause cell death). In contrast, e-cigarette vapor is neither genotoxic nor cytotoxic, even at extremely high doses.’

    “We know that we can be confident in our results because we have shown that e-cigarette aerosol droplets are effectively delivered to cell surfaces in lab-based biological tests,” said Murphy.

    BAT made the point that many in the public health community believe electronic cigarettes offer great potential for reducing the public health impact of smoking. ‘Public Health England, an executive body of the UK Department of Health, recently published a report saying that the current expert estimate is that using e-cigarettes is around 95 percent safer than smoking cigarettes, although more research is needed,’ reported BAT. ‘The Royal College of Physicians have said that the public can be reassured that e-cigarettes are much safer then smoking and that they should be widely promoted as an alternative to cigarettes.’

  • E-cigarette info for parents

    E-cigarette info for parents

    vapor-e-cigaretteThe National Center on Addiction and Substance Abuse in New York launched a new online resource, called “Expert views: e-cigarettes,” as part of efforts to help parents better understand vapor products, including the health risks/benefits of the devices and whether they aid smoking cessation.

    The center has hired global public relations agency Porter Novelli to conduct an online audit, which found that much of the information available about the use, risks and benefits of eVapor products is inconsistent, inaccurate and confusing.

    Linda Richter, director of policy research and analysis at the center, said the use of the devices among young people and the prevailing perception that vaping is harmless “highlight the tobacco industry’s ability to dominate public impressions about the safety of these products.”

    Samuel A. Ball, president and CEO at the center, said the resource is aimed at helping the public “make sense of the often confusing and contradictory information that is available on the risks and benefits of e-cigarettes and to help parents exercise the critical influence we know they have on their children’s choices regarding nicotine use.”

  • Nicotine improves cognitive function

    Nicotine improves cognitive function

    thinkingA PhD graduate at the Victoria University of Wellington, New Zealand, has said that her study into the link between tobacco smoking and schizophrenia should prompt a re-think of smoking bans in hospitals, according to a story by Ged Cann for stuff.co.nz.

    The study found that smoking could alleviate some symptoms of schizophrenia, and, according to the study’s author, Uta Waterhouse, this raised the question of whether current legislation, which prohibits smoking in places such as hospitals and other healthcare facilities, might be having adverse effects on schizophrenic patients.

    Smoking rates among people with schizophrenia are between 75 percent and 90 percent, while the rate among people with other mental disorders is about 50 percent and that among the general population is about 20 percent.

    Waterhouse said her research had found that nicotine improved the cognitive deficits associated with schizophrenia.

    These deficits included a reduced ability to focus on a task, ignore irrelevant information, and inhibit a startle response.

    Otago University senior lecturer in psychological medicine Giles Newton-Howes was quoted as saying that he had serious concerns about Waterhouse’s research being used to influence policy. Nicotine was a stimulant, so you expect it to improve most peoples’ cognitive function, he said.

  • The passion pit

    The passion pit

    Stakeholders talk nicotine in Warsaw

    By George Gay

    Just before the start of the consumer advocates meeting, which was one of three parallel sessions that kicked off the Global Forum on Nicotine (GFN) in June, one of the panelists asked another, “Who’s in charge?”

    It was to prove to have been a good question. Although the meeting was well-run (in Euro 2016 football competition terms, say, the referee let the game flow), there was always a sense that anarchy could break out at any moment—an anarchy born of passion. Of course, there was plenty of passion to be found elsewhere at the forum as scientists showed their frustration at having to counter the media stories emerging from the publication of poorly designed and misleading studies into noncombustible tobacco and nicotine products, and as tobacco control advocates expressed dismay that some of their colleagues refused to embrace the concept of smoking harm reduction. But such academic passion is not on the same scale as the passion stirred in people who believe that various authorities are trying to ban or restrict products those people see as lifesaving and, indeed, life-enhancing.

    In fact, though the 2016 GFN, which was held in Warsaw, Poland, had as its theme “Evidence, accountability, transparency,” a subtheme was surely passion. And there should be no surprise here. This year’s GFN, the third such meeting, attracted 350 participants—including 40 speakers—from 55 countries, which put it a little over capacity. It attracted consumers, scientists, regulators, manufacturers, distributors, public health professionals, policy analysts and media representatives. And, crucially, these participants came in different shapes and sizes; so, unlike at some conferences, they weren’t all in agreement.

    Lack of vision

    In fact, the passion was there from before the start of the formal sessions on June 17 and June 18 because, prior to the forum’s social event on the evening of June 16, participants had the opportunity to attend a viewing of A Billion Lives, a documentary by Aaron Biebert that traced the history of the tobacco industry and the emergence of lower-risk products, mainly vapor products. The documentary showed, with a passion that film can provide so well, how the promise of these new lower-risk products was in danger of being squandered by some of those with vested interests in their not being successful and by those too set in their ways to embrace this new phenomenon. And clearly there are a lot of people with such vested interests and with such lack of vision.

    Step forward the World Health Organization with what one forum participant described as its policy-based evidence, and its secretive offspring, the Framework Convention on Tobacco Control with its bizarre—given that it is purportedly committed to harm reduction—insistence that smokers consume licit cigarettes rather than illicit cigarettes—or, heaven forfend, vapor products.

    Step forward the EU Commission and its revised Tobacco Products Directive with its vapor product provisions seemingly aimed at nagging these products out of existence. And step forward the U.S. Food and Drug Administration (FDA) with a perfect demonstration of the science of obfuscation. The FDA has taken a long look at vapor products and turned what is a simple concept into an incredibly complex one. If the courts don’t rein in this agency, it will strangle these products in gobbledygook, which should be the subject of prominent, graphic health warnings. The irony is that in the one area where consumers could use some help—the area of exploding batteries—the relevant agencies seem to have completely failed.

    If these organizations cannot help consumers, they should be removed from this field. Consumers are perfectly capable of navigating their way around vapor products. And as one forum participant suggested, vapor products are simply not risky enough to spend energy and resources on regulations beyond those to do with their construction.

    Passion and compassion

    But perhaps the forum’s passion subtheme should be expanded. One of the participants said that she had been hugely encouraged by the passion and compassion that she had seen displayed during the event. And her observation was spot on. A vapor advocate who spoke made the point that while the vapor sector had made alliances with various groups, including with public health, smokers had tended to be sidelined. He asked whether it wasn’t time to invite smokers—whom he described as the nine-tenths of the smoking/vaping iceberg still submerged—to take part in the debate. That is worth thinking about from two perspectives: from the perspective of whether this isn’t a good idea in itself, and from the perspective of how a person fighting against the odds to advance the cause of vaping still had enough energy, courage and compassion to speak out on behalf of those who so far have continued to smoke.

    He wasn’t alone. A number of speakers made the point, one way or another, that while smokers should be encouraged to quit their habit, they shouldn’t be bullied into doing so by being marginalized socially or being ground under foot by unconscionable levels of taxation. In fact, the word “quit” seems to be becoming something of a dirty word. Smokers shouldn’t be encouraged to quit, it was said, but to shift to less risky products.

    There was, in fact, a general groundswell of sympathy for smokers, who tend to be relatively less well-off financially. It was pointed out on a number of occasions that these smokers, especially those living outside the developed countries, but in some cases indigenous people living in developed countries, would find it difficult if not impossible to access vapor products, given the initial outlay necessary. And in the future, of course, it is possible if not likely that vapor products will, like cigarettes, be taxed.

    If this is starting to make the forum sound like a late 1960s love-in, that’s probably because it was to some extent. And, of course, there are dangers here. As Mr. Lebowski was all too keen to point out: “Condolences! The bums lost!” But while there are similarities with the late 1960s, there are differences, too. The dreams of the 1960s were summoned up partly by the consumption of illicit products, whereas the movement in evidence in Warsaw is based partly on—in most places at least—a licit product. Also, importantly, in the 1960s the “straight” community was still in thrall to the existing social, economic and political structures, whereas now it is looking at structures fracturing in the realization, post-2008, that they are, if not rotten, in need of considerable remedial work.

    Division

    I have to step a little carefully here because I have introduced a division between licit and illicit products, and the GFN was most decidedly not about division. One speaker made the point that the use of heroin blighted lives, not because it was inherently dangerous but because its categorization as illicit often led to the use of contaminated equipment to deliver a degraded product obtained from criminals.

    But there was one division that I noticed, and that was in A Billion Lives, where there were no interviews with the major tobacco manufacturers about harm reduction. I can understand why this was the case, but I think it was a pity. Say what you like about the major tobacco manufacturers, but, after a late start, they seem in general to be trying to advance the cause of harm reduction. It might be the case that independent suppliers of vapor products are more consumer-friendly and more innovative, and it might be the case that the major tobacco manufacturers are seen to be being handed an advantage because of their ability more easily to meet regulatory demands, but it has to be acknowledged that the bigger manufacturers have the financial and intellectual resources to make an important contribution.

    To my way of thinking, the film dwelled too long upon the undoubted misdeeds of tobacco manufacturers in the past. These are generally well-known. What we need to focus on—as indeed the film did—is the one thing that matters: helping those smokers who want to do so to shift from tobacco cigarettes to less risky cigarette substitute products. This is certainly not, to my mind, an argument for increasing the participation of the major tobacco manufacturers at the GFN; they can all too easily take over such forums. And I don’t think that anybody should take their eyes off these companies’ lobbying and competitive arrangements. But it is undoubtedly the case that their scientists have an important contribution to make to debates surrounding harm reduction.

    I should point out, however, that while the film sidelined the major manufacturers in respect of harm reduction, the GFN and its participants didn’t. At the start of the consumer advocates meeting, attendees were asked to explain who they were, and one person, representing a major manufacturer, added that he was sitting at the back in case the other attendees tried to kill him. But I can report that the man left the session unharmed.

    Which is how it should have been. The forum, after all, was largely about harm reduction. Journalists were told during a press conference before the opening that the number of smokers was increasing worldwide and that during this century 1 billion people were expected to die prematurely from causes related to smoking. But while there were available nicotine-delivery devices whose consumption was 90–95 percent less harmful than was smoking, some people and organizations were discouraging their use through the application of bad science, scaremongering and poor legislation, often concocted behind closed doors. As one person said, people had been lied to—they had been told that vaping was as harmful as was smoking.

    The encouraging thing is that in some jurisdictions at least consumers are savvier than they are perhaps given credit for. The point was made well enough that, for some people, e-cigarettes made giving up smoking enjoyable, which is presumably why 6.1 million people in the 28 member states of the EU are said to have quit smoking using vapor products. (It is necessary to say “quit” here because some of those who stopped smoking might also now have stopped vaping.)

    But consumers have to be given a fair go. It is worth mentioning that the severity with which some countries treat people involved in the e-cigarette trade is difficult to comprehend, given that all but the one-eyed must admit these products have the potential for delivering huge public health improvements. It was mentioned during the advocates meeting with which this piece starts that people in Australia and India had been treated with what I could only describe as irrational vindictiveness. It makes you wonder who is in charge of such matters in these countries.

    The GFN presentations are at: https://gfn.net.co/2016-presentations.